25 XP   0   0   10

Galera Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Galera Therapeutics Inc together

PenkeI guess you are interested in Galera Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galera Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Galera Therapeutics Inc

I send you an email if I find something interesting about Galera Therapeutics Inc.

Quick analysis of Galera Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Galera Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.33
Expected worth in 1 year
$-2.86
How sure are you?
19.0%

+ What do you gain per year?

Total Gains per Share
$-0.53
Return On Investment
-347.9%

For what price can you sell your share?

Current Price per Share
$0.15
Expected price per share
$0.124 - $0.2039
How sure are you?
50%

1. Valuation of Galera Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.15

Intrinsic Value Per Share

$-5.15 - $-5.77

Total Value Per Share

$-7.48 - $-8.10

2. Growth of Galera Therapeutics Inc (5 min.)




Is Galera Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$126.5m-$77.3m-$34.7m-31.0%

How much money is Galera Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$19.4m-$17.7m-$1.7m-8.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Galera Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1015 / 1031

Most Revenue
#977 / 1031

Most Profit
#722 / 1031

Most Efficient
#432 / 1031

What can you expect buying and holding a share of Galera Therapeutics Inc? (5 min.)

Welcome investor! Galera Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Galera Therapeutics Inc.

What can you expect buying and holding a share of Galera Therapeutics Inc?

First you should know what it really means to hold a share of Galera Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Galera Therapeutics Inc is $0.1535. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galera Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galera Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.33. Based on the TTM, the Book Value Change Per Share is $-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galera Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-180.5%-0.32-208.7%-0.29-188.2%-0.31-203.7%-0.30-197.8%
Usd Book Value Change Per Share-0.21-138.4%-0.13-87.0%-0.25-162.7%-0.17-112.4%-0.11-72.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-138.4%-0.13-87.0%-0.25-162.7%-0.17-112.4%-0.11-72.2%
Usd Price Per Share0.18-1.84-2.50-4.66-4.44-
Price to Earnings Ratio-0.16--1.36--2.12--3.38--3.22-
Price-to-Total Gains Ratio-0.82--1.37--9.85--15.88--15.88-
Price to Book Ratio-0.08--0.93--1.99-2.62-2.49-
Price-to-Total Gains Ratio-0.82--1.37--9.85--15.88--15.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1535
Number of shares6514
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.13-0.17
Usd Total Gains Per Share-0.13-0.17
Gains per Quarter (6514 shares)-869.79-1,123.56
Gains per Year (6514 shares)-3,479.14-4,494.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3479-34890-4494-4504
20-6958-69680-8988-8998
30-10437-104470-13483-13492
40-13917-139260-17977-17986
50-17396-174050-22471-22480
60-20875-208840-26965-26974
70-24354-243630-31460-31468
80-27833-278420-35954-35962
90-31312-313210-40448-40456
100-34791-348000-44942-44950

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.016.01.015.0%4.016.01.019.0%4.016.01.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.016.01.015.0%4.016.01.019.0%4.016.01.019.0%

Fundamentals of Galera Therapeutics Inc

About Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Fundamental data was last updated by Penke on 2024-03-20 19:38:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Galera Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Galera Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Galera Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • -39.9% Return on Assets means that Galera Therapeutics Inc generated $-0.40 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galera Therapeutics Inc:

  • The MRQ is -39.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -40.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.9%TTM-40.7%+0.8%
TTM-40.7%YOY-27.7%-13.0%
TTM-40.7%5Y-23.9%-16.8%
5Y-23.9%10Y-23.1%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.9%-12.5%-27.4%
TTM-40.7%-12.2%-28.5%
YOY-27.7%-11.2%-16.5%
5Y-23.9%-13.4%-10.5%
10Y-23.1%-14.7%-8.4%
1.1.3. Return on Equity

Shows how efficient Galera Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Galera Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-26.5%+26.5%
5Y-26.5%10Y-25.3%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM--15.7%+15.7%
YOY--13.9%+13.9%
5Y-26.5%-18.3%-8.2%
10Y-25.3%-19.2%-6.1%

1.2. Operating Efficiency of Galera Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Galera Therapeutics Inc is operating .

  • Measures how much profit Galera Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galera Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Galera Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of Galera Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Galera Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.47 means the company has $2.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 2.474. The company is able to pay all its short-term debts. +1
  • The TTM is 3.132. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.474TTM3.132-0.658
TTM3.132YOY5.210-2.078
TTM3.1325Y6.797-3.666
5Y6.79710Y7.093-0.296
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4743.986-1.512
TTM3.1324.440-1.308
YOY5.2105.552-0.342
5Y6.7976.158+0.639
10Y7.0936.492+0.601
1.3.2. Quick Ratio

Measures if Galera Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.56 means the company can pay off $2.56 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 2.561. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.094. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.561TTM4.094-1.533
TTM4.094YOY8.244-4.150
TTM4.0945Y10.721-6.627
5Y10.72110Y10.710+0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5613.638-1.077
TTM4.0944.168-0.074
YOY8.2445.515+2.729
5Y10.7216.012+4.709
10Y10.7106.209+4.501

1.4. Solvency of Galera Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Galera Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Galera Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 4.35 means that Galera Therapeutics Inc assets are financed with 435.0% credit (debt) and the remaining percentage (100% - 435.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 4.350. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.461. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ4.350TTM3.461+0.888
TTM3.461YOY2.243+1.218
TTM3.4615Y1.805+1.657
5Y1.80510Y1.734+0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3500.335+4.015
TTM3.4610.330+3.131
YOY2.2430.267+1.976
5Y1.8050.367+1.438
10Y1.7340.378+1.356
1.4.2. Debt to Equity Ratio

Measures if Galera Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galera Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.053-1.053
5Y1.05310Y1.003+0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY-0.334-0.334
5Y1.0530.429+0.624
10Y1.0030.476+0.527

2. Market Valuation of Galera Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Galera Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Galera Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.16 means the investor is paying $-0.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.138. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.158. Based on the earnings, the company is expensive. -2
  • The TTM is -1.356. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.138MRQ-0.158+0.019
MRQ-0.158TTM-1.356+1.198
TTM-1.356YOY-2.125+0.769
TTM-1.3565Y-3.382+2.026
5Y-3.38210Y-3.221-0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.138-2.643+2.505
MRQ-0.158-2.418+2.260
TTM-1.356-2.742+1.386
YOY-2.125-4.123+1.998
5Y-3.382-6.257+2.875
10Y-3.221-6.478+3.257
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.167. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.190. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.139. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.167MRQ-0.190+0.023
MRQ-0.190TTM-2.139+1.949
TTM-2.139YOY-2.740+0.601
TTM-2.1395Y-4.293+2.154
5Y-4.29310Y-4.089-0.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.167-3.244+3.077
MRQ-0.190-2.939+2.749
TTM-2.139-3.478+1.339
YOY-2.740-5.592+2.852
5Y-4.293-8.473+4.180
10Y-4.089-8.881+4.792
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Galera Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.08 means the investor is paying $-0.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Galera Therapeutics Inc:

  • The EOD is -0.066. Based on the equity, the company is expensive. -2
  • The MRQ is -0.075. Based on the equity, the company is expensive. -2
  • The TTM is -0.930. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.066MRQ-0.075+0.009
MRQ-0.075TTM-0.930+0.855
TTM-0.930YOY-1.990+1.060
TTM-0.9305Y2.616-3.546
5Y2.61610Y2.491+0.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0662.124-2.190
MRQ-0.0752.041-2.116
TTM-0.9302.118-3.048
YOY-1.9902.915-4.905
5Y2.6163.682-1.066
10Y2.4914.114-1.623
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Galera Therapeutics Inc.

3.1. Institutions holding Galera Therapeutics Inc

Institutions are holding 28.81% of the shares of Galera Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31GSA Capital Partners LLP7.15650.0476389256138925610
2023-12-31Sofinnova Ventures5.66940.0251308371200
2023-12-31Blackstone Inc3.08680.0011167898400
2023-12-31abrdn PLC1.65170.00038983748983740
2023-12-31Vanguard Group Inc0.82430448330-608547-57.5797
2023-12-31Geode Capital Management, LLC0.8096044034912712340.5851
2023-12-31BlackRock Inc0.65750357622-13021-3.5131
2023-12-31Renaissance Technologies Corp0.57640.00013135003135000
2023-12-31State Street Corporation0.1959010656400
2023-12-31Northern Trust Corp0.126906902900
2023-12-31Group One Trading, LP0.119306489700
2023-12-31Virtu Financial LLC0.10390.00065648744185359.1692
2023-12-31XTX Topco Ltd0.0730.001339726397260
2023-12-31Royal Bank of Canada0.06590358247322.0859
2023-12-31Kestra Advisory Services, LLC0.0657035750-50000-58.309
2023-12-31Good Life Advisors, LLC0.05750.00053125000
2023-12-31Level Four Advisory Services, LLC0.04860.00022644100
2023-12-31Bank of New York Mellon Corp0.040502202000
2023-12-31Manchester Financial Inc0.04040.000922000-27900-55.9118
2023-12-31Vontobel Holding Ltd.0.036802000000
Total 21.40660.077711643420+4616733+39.7%

3.2. Funds holding Galera Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.82430.000144833000
2024-01-31abrdn Healthcare Opportunities0.57810.005131443000
2024-01-31abrdn Healthcare Investors0.5450.005329646200
2024-01-31Fidelity Extended Market Index0.43530.000123679000
2024-01-31abrdn World Healthcare0.29730.00516170900
2024-01-31abrdn Life Sciences Investors0.23120.005112577300
2023-09-30Bridgeway Ultra-Small Company Market0.19890.011310820000
2024-02-29iShares Micro-Cap ETF0.16440.00248942400
2024-01-31Fidelity Nasdaq Composite Index0.16350.00018891500
2023-09-30BlackRock Extended Mkt Composite0.12070.00016562500
2023-12-31BlackRock Extended Equity Market K0.10530.000157252-115-0.2005
2024-01-31Fidelity Series Total Market Index0.077804233400
2024-01-31Fidelity Total Market Index0.069803796900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06710.00013651400
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05440.00012957300
2023-12-31Northern Trust Extended Eq Market Idx0.05440.00012957300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05390.000129326550.1879
2024-01-31Spartan Total Market Index Pool E0.041702266000
2023-06-30Zeus Capital SICAV DNA Biotech B Acc0.02571.943114000140000
2024-01-31Spartan Extended Market Index Pool E0.02050.00011116700
Total 4.12931.97832246026+13940+0.6%

3.3. Insider Transactions

Insiders are holding 20.162% of the shares of Galera Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-03-16Mark BachledaBUY110002.25
2023-03-13Chris DegnanBUY100001.96
2023-03-10Mel SorensenBUY1000001.68
2021-12-17Linda WestBUY200002.74
2021-06-15Linda WestBUY100009.13
2021-06-02Linda WestBUY100008.65

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Galera Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.212-0.134-37%-0.250+18%-0.172-19%-0.111-48%
Book Value Per Share---2.327-2.061-11%-1.421-39%-0.746-68%-0.657-72%
Current Ratio--2.4743.132-21%5.210-53%6.797-64%7.093-65%
Debt To Asset Ratio--4.3503.461+26%2.243+94%1.805+141%1.734+151%
Debt To Equity Ratio----0%-0%1.053-100%1.003-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.277-0.320+16%-0.289+4%-0.313+13%-0.304+10%
Free Cash Flow Per Share---0.230-0.225-2%-0.216-6%-0.240+4%-0.233+1%
Free Cash Flow To Equity Per Share---0.191-0.067-65%-0.210+10%-0.037-81%0.022-981%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.770--------
Intrinsic Value_10Y_min---5.153--------
Intrinsic Value_1Y_max---0.940--------
Intrinsic Value_1Y_min---0.924--------
Intrinsic Value_3Y_max---2.549--------
Intrinsic Value_3Y_min---2.439--------
Intrinsic Value_5Y_max---3.825--------
Intrinsic Value_5Y_min---3.574--------
Market Cap8349202.700-14%9518635.00099877677.250-90%136116480.500-93%253399661.750-96%241333011.190-96%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-0.066+12%-0.075-0.930+1136%-1.990+2546%2.616-103%2.491-103%
Pe Ratio-0.138+12%-0.158-1.356+759%-2.125+1246%-3.382+2042%-3.221+1940%
Price Per Share0.154-14%0.1751.836-90%2.503-93%4.659-96%4.437-96%
Price To Free Cash Flow Ratio-0.167+12%-0.190-2.139+1026%-2.740+1342%-4.293+2159%-4.089+2051%
Price To Total Gains Ratio-0.723+12%-0.824-1.372+67%-9.846+1095%-15.882+1828%-15.882+1828%
Quick Ratio--2.5614.094-37%8.244-69%10.721-76%10.710-76%
Return On Assets---0.399-0.407+2%-0.277-31%-0.239-40%-0.231-42%
Return On Equity----0%-0%-0.2650%-0.2530%
Total Gains Per Share---0.212-0.134-37%-0.250+18%-0.172-19%-0.111-48%
Usd Book Value---126553000.000-112086500.000-11%-77305750.000-39%-40595800.000-68%-35754000.000-72%
Usd Book Value Change Per Share---0.212-0.134-37%-0.250+18%-0.172-19%-0.111-48%
Usd Book Value Per Share---2.327-2.061-11%-1.421-39%-0.746-68%-0.657-72%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.277-0.320+16%-0.289+4%-0.313+13%-0.304+10%
Usd Free Cash Flow---12521000.000-12232000.000-2%-11751250.000-6%-13044000.000+4%-12664666.667+1%
Usd Free Cash Flow Per Share---0.230-0.225-2%-0.216-6%-0.240+4%-0.233+1%
Usd Free Cash Flow To Equity Per Share---0.191-0.067-65%-0.210+10%-0.037-81%0.022-981%
Usd Market Cap8349202.700-14%9518635.00099877677.250-90%136116480.500-93%253399661.750-96%241333011.190-96%
Usd Price Per Share0.154-14%0.1751.836-90%2.503-93%4.659-96%4.437-96%
Usd Profit---15073000.000-19433750.000+29%-17701750.000+17%-17348950.000+15%-16772761.905+11%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.212-0.134-37%-0.250+18%-0.172-19%-0.111-48%
 EOD+2 -6MRQTTM+6 -21YOY+11 -165Y+10 -1810Y+10 -18

4.2. Fundamental Score

Let's check the fundamental score of Galera Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.138
Price to Book Ratio (EOD)Between0-1-0.066
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.561
Current Ratio (MRQ)Greater than12.474
Debt to Asset Ratio (MRQ)Less than14.350
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.399
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Galera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.853
Ma 20Greater thanMa 500.225
Ma 50Greater thanMa 1000.201
Ma 100Greater thanMa 2000.173
OpenGreater thanClose0.180
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets37,779
Total Liabilities164,332
Total Stockholder Equity-126,553
 As reported
Total Liabilities 164,332
Total Stockholder Equity+ -126,553
Total Assets = 37,779

Assets

Total Assets37,779
Total Current Assets31,245
Long-term Assets6,534
Total Current Assets
Cash And Cash Equivalents 24,379
Short-term Investments 3,985
Other Current Assets 2,831
Total Current Assets  (as reported)31,245
Total Current Assets  (calculated)31,195
+/- 50
Long-term Assets
Property Plant Equipment 1,447
Goodwill 881
Intangible Assets 2,258
Long-term Assets Other 1,948
Long-term Assets  (as reported)6,534
Long-term Assets  (calculated)6,534
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,630
Long-term Liabilities151,702
Total Stockholder Equity-126,553
Total Current Liabilities
Short-term Debt 131
Accounts payable 3,715
Other Current Liabilities 8,784
Total Current Liabilities  (as reported)12,630
Total Current Liabilities  (calculated)12,630
+/-0
Long-term Liabilities
Capital Lease Obligations 1,286
Long-term Liabilities Other 150,344
Long-term Liabilities  (as reported)151,702
Long-term Liabilities  (calculated)151,630
+/- 72
Total Stockholder Equity
Common Stock54
Retained Earnings -431,819
Other Stockholders Equity 305,212
Total Stockholder Equity (as reported)-126,553
Total Stockholder Equity (calculated)-126,553
+/-0
Other
Capital Stock54
Cash and Short Term Investments 28,364
Common Stock Shares Outstanding 45,478
Liabilities and Stockholders Equity 37,779
Net Debt -23,093
Net Invested Capital -126,553
Net Working Capital 18,615
Property Plant and Equipment Gross 2,340
Short Long Term Debt Total 1,286



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
> Total Assets 
88,056
88,056
91,043
91,043
79,758
123,376
130,813
114,295
98,075
84,098
70,486
115,269
98,765
83,311
71,099
61,078
50,713
44,036
59,714
48,276
37,779
37,77948,27659,71444,03650,71361,07871,09983,31198,765115,26970,48684,09898,075114,295130,813123,37679,75891,04391,04388,05688,056
   > Total Current Assets 
83,852
83,852
83,951
83,951
72,142
117,570
125,018
108,398
92,304
77,929
64,240
108,864
92,688
77,392
65,276
55,188
44,917
38,535
54,243
42,003
31,245
31,24542,00354,24338,53544,91755,18865,27677,39292,688108,86464,24077,92992,304108,398125,018117,57072,14283,95183,95183,85283,852
       Cash And Cash Equivalents 
14,811
14,811
16,195
16,195
15,719
18,356
21,578
15,882
15,232
15,872
13,687
38,465
17,632
19,859
19,645
17,376
12,730
4,266
25,687
24,302
24,379
24,37924,30225,6874,26612,73017,37619,64519,85917,63238,46513,68715,87215,23215,88221,57818,35615,71916,19516,19514,81114,811
       Short-term Investments 
66,706
66,706
65,082
65,082
52,226
93,934
98,939
88,527
73,919
56,904
43,833
28,062
71,073
51,358
41,302
34,631
30,039
27,331
22,064
14,453
3,985
3,98514,45322,06427,33130,03934,63141,30251,35871,07328,06243,83356,90473,91988,52798,93993,93452,22665,08265,08266,70666,706
       Net Receivables 
914
870
0
0
0
0
0
0
0
0
0
37,500
0
0
0
0
0
3,242
0
0
0
0003,2420000037,500000000000870914
       Other Current Assets 
0
1,465
0
2,674
4,197
5,280
4,501
3,989
3,153
5,153
6,720
4,837
3,983
6,175
4,329
3,181
2,148
6,888
6,442
3,198
2,831
2,8313,1986,4426,8882,1483,1814,3296,1753,9834,8376,7205,1533,1533,9894,5015,2804,1972,67401,4650
   > Long-term Assets 
0
4,204
0
7,092
7,616
5,806
5,795
5,897
5,771
6,169
6,246
6,405
6,077
5,919
5,823
5,890
5,796
5,501
5,471
6,273
6,534
6,5346,2735,4715,5015,7965,8905,8235,9196,0776,4056,2466,1695,7715,8975,7955,8067,6167,09204,2040
       Property Plant Equipment 
568
568
1,890
1,890
1,846
1,749
1,637
1,840
1,676
1,553
1,630
1,470
1,312
823
738
654
570
481
418
1,496
1,447
1,4471,4964184815706547388231,3121,4701,6301,5531,6761,8401,6371,7491,8461,8901,890568568
       Goodwill 
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881
881881881881881881881881881881881881881881881881881881881881881
       Intangible Assets 
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,258
2,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,2582,258
       Long-term Assets Other 
0
497
0
2,063
2,631
918
1,019
918
956
1,477
1,477
1,796
1,626
1,957
1,946
2,097
2,087
1,881
1,914
1,638
1,948
1,9481,6381,9141,8812,0872,0971,9461,9571,6261,7961,4771,4779569181,0199182,6312,06304970
> Total Liabilities 
26,974
192,876
50,726
50,726
224,378
53,768
77,755
74,058
73,380
77,980
81,059
140,786
141,932
141,315
141,570
144,324
148,215
153,217
157,327
163,275
164,332
164,332163,275157,327153,217148,215144,324141,570141,315141,932140,78681,05977,98073,38074,05877,75553,768224,37850,72650,726192,87626,974
   > Total Current Liabilities 
6,444
6,444
8,355
8,355
9,083
9,694
12,648
12,402
10,503
13,968
15,855
16,843
15,724
12,935
10,931
10,986
11,632
13,379
13,266
13,622
12,630
12,63013,62213,26613,37911,63210,98610,93112,93515,72416,84315,85513,96810,50312,40212,6489,6949,0838,3558,3556,4446,444
       Short-term Debt 
0
0
0
286
291
297
285
268
250
238
296
284
271
258
234
172
109
44
0
128
131
131128044109172234258271284296238250268285297291286000
       Accounts payable 
3,867
3,867
5,470
5,470
5,218
3,945
6,640
6,767
4,013
5,146
9,217
8,272
7,181
5,044
4,131
3,588
3,591
3,581
5,937
5,516
3,715
3,7155,5165,9373,5813,5913,5884,1315,0447,1818,2729,2175,1464,0136,7676,6403,9455,2185,4705,4703,8673,867
       Other Current Liabilities 
0
2,577
0
2,599
3,574
5,452
5,723
5,367
6,240
8,584
6,342
8,287
8,272
7,633
6,566
7,226
7,932
9,754
7,329
7,978
8,784
8,7847,9787,3299,7547,9327,2266,5667,6338,2728,2876,3428,5846,2405,3675,7235,4523,5742,59902,5770
   > Long-term Liabilities 
0
186,432
0
42,371
215,295
44,074
65,107
61,656
62,877
64,012
65,204
123,943
126,208
128,380
130,639
133,338
136,583
139,838
144,061
149,653
151,702
151,702149,653144,061139,838136,583133,338130,639128,380126,208123,94365,20464,01262,87761,65665,10744,074215,29542,3710186,4320
       Long term Debt Total 
0
20,220
0
41,395
42,313
43,251
64,346
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000064,34643,25142,31341,395020,2200
       Capital Lease Obligations Min Short Term Debt
0
0
0
678
604
534
472
414
356
296
235
172
110
44
0
0
0
0
0
1,193
1,155
1,1551,1930000044110172235296356414472534604678000
       Long-term Liabilities Other 
0
0
0
41,395
42,313
43,251
64,346
60,953
62,232
64,012
65,204
123,498
125,825
128,063
130,366
133,065
136,310
139,838
144,061
148,257
150,344
150,344148,257144,061139,838136,310133,065130,366128,063125,825123,49865,20464,01262,23260,95364,34643,25142,31341,395000
       Deferred Long Term Liability 
0
0
1,747
1,747
2,103
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,1031,7471,74700
> Total Stockholder Equity
-104,820
-104,820
-129,656
40,317
-144,620
69,608
53,058
40,237
24,695
6,118
-10,573
-25,517
-43,167
-58,004
-70,471
-83,246
-97,502
-109,181
-97,613
-114,999
-126,553
-126,553-114,999-97,613-109,181-97,502-83,246-70,471-58,004-43,167-25,517-10,5736,11824,69540,23753,05869,608-144,62040,317-129,656-104,820-104,820
   Common Stock
2
2
2
19
-344,160
25
25
25
25
25
25
26
26
26
27
27
27
28
43
44
54
54444328272727262626252525252525-344,16019222
   Retained Earnings -431,819-416,746-396,034-378,324-362,136-346,103-331,545-316,102-299,295-276,669-254,283-235,568-215,502-198,424-179,767-161,350-144,675-129,737-129,739-104,823-104,825
   Capital Surplus 
0
0
0
0
0
230,895
232,114
0
0
241,649
243,675
251,123
0
0
0
0
0
269,137
298,362
0
0
00298,362269,13700000251,123243,675241,64900232,114230,89500000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
3
210
81
169,954
172,080
230,895
232,114
238,320
240,049
241,649
243,675
251,123
256,104
258,086
261,108
262,940
264,700
269,137
298,362
301,698
305,212
305,212301,698298,362269,137264,700262,940261,108258,086256,104251,123243,675241,649240,049238,320232,114230,895172,080169,954812103



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-54,960
Operating Income-54,960-54,960
 
Operating Expense (+$)
Research Development29,090
Selling General Administrative25,870
Selling And Marketing Expenses-
Operating Expense54,96054,960
 
Net Interest Income (+$)
Interest Income1,550
Interest Expense-14,033
Other Finance Cost-0
Net Interest Income-12,483
 
Pretax Income (+$)
Operating Income-54,960
Net Interest Income-12,483
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-69,753-52,650
EBIT - interestExpense = -14,033
-69,683
-55,650
Interest Expense14,033
Earnings Before Interest and Taxes (EBIT)--55,720
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-69,753
Tax Provision--
Net Income From Continuing Ops-69,683-69,753
Net Income-69,683
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-2,31012,483
 

Technical Analysis of Galera Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Galera Therapeutics Inc. The general trend of Galera Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Galera Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Galera Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.157 < 0.1585 < 0.2039.

The bearish price targets are: 0.164 > 0.159 > 0.124.

Tweet this
Galera Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Galera Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Galera Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Galera Therapeutics Inc. The current macd is -0.00119226.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galera Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Galera Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Galera Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Galera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartGalera Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Galera Therapeutics Inc. The current adx is 25.25.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Galera Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Galera Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Galera Therapeutics Inc. The current sar is 0.25979959.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Galera Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Galera Therapeutics Inc. The current rsi is 31.85. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Galera Therapeutics Inc Daily Relative Strength Index (RSI) ChartGalera Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Galera Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galera Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Galera Therapeutics Inc Daily Stochastic Oscillator ChartGalera Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Galera Therapeutics Inc. The current cci is -282.10144928.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Galera Therapeutics Inc Daily Commodity Channel Index (CCI) ChartGalera Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Galera Therapeutics Inc. The current cmo is -54.67759317.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Galera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartGalera Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Galera Therapeutics Inc. The current willr is -97.96672828.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Galera Therapeutics Inc Daily Williams %R ChartGalera Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Galera Therapeutics Inc.

Galera Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Galera Therapeutics Inc. The current atr is 0.02629701.

Galera Therapeutics Inc Daily Average True Range (ATR) ChartGalera Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Galera Therapeutics Inc. The current obv is 26,836,005.

Galera Therapeutics Inc Daily On-Balance Volume (OBV) ChartGalera Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Galera Therapeutics Inc. The current mfi is 23.66.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Galera Therapeutics Inc Daily Money Flow Index (MFI) ChartGalera Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Galera Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Galera Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Galera Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.853
Ma 20Greater thanMa 500.225
Ma 50Greater thanMa 1000.201
Ma 100Greater thanMa 2000.173
OpenGreater thanClose0.180
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Galera Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Galera Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Galera Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Galera Therapeutics Inc

I send you an email if I find something interesting about Galera Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Galera Therapeutics Inc.

Receive notifications about Galera Therapeutics Inc in your mailbox!